Folks, Vericel announced today that it received FDA Fast Track designation for its ixmyelocel‑T product for treatment of advanced heart failure due to dilated cardiomyopathy.
So why am I posting this news about Vericel on this board?
Let's compare Mesoblast to Vericel.
Back in April 2016, Vericel's ixmyelocel‑T product failed to meet it's secondary endpoints of heart-pumping efficiency and six-minute walking distance in the Phase 2b trial.
You read that right - it FAILED to meet it's secondary endpoints. And that was in the Phase 2b trial.
Plus, ixmyelocel‑T is autologous, which means it takes a patient's own stem cells.
As opposed to allogeneic, which is Mesoblast's products. Lookup the comparison advantages of allogeneic vs. autologous especially with respect to mass commercialization and ready, off-the-shelf availability.
Mesoblast's CHF therapy is light years ahead of Vericel's in its efficacy and commercial viability.
And Mesoblast is way past Phase 2 in CHF.
So. The. FDA. Just. Granted. Vericel. Fast. Track. Designation for its ixmyelocel‑T product.
Over and out.
Tick, tock, tick, tock..............
Heart Failure
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
0.045(3.33%) |
Mkt cap ! $1.592B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.42 | $1.33 | $3.802M | 2.753M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 23940 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 22571 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |